Raltegravir News and Research

RSS

MSD's ISENTRESS approved by the EU Commission for treating HIV-1 infection in adult patients

Merck Sharp & Dohme Limited (MSD) announced today that ISENTRESS® (raltegravir) has been granted an expanded licence from the European Union Commission (Commission) for use in combination with other antiretroviral (ARV) medicinal products for the treatment of HIV-1 infection in adult patients, including adult patients starting HIV-1 therapy for the first time (treatment-naïve), as well as treatment-experienced adult patients.

15 Sep 2009

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

ISENTRESS , an integrase inhibitor from Merck & Co., Inc., was studied in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL) and at improving CD4 cell counts in previously untreated (treatment-naïve) HIV-1-infected patients through 96 weeks in a Phase III study called STARTMRK.

14 Sep 2009

Tobira Therapeutics presents TBR-652 in vitro data for treating HIV at the 49th ICAAC

Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced results from an in vitro study evaluating TBR-652 in combination with lopinavir (LPV), darunavir (DRV), atazanavir (ATV), tenofovir (TDF), etravirine (ETV), and raltegravir (RAL) using the infectious replicative assay deCIPhR.

14 Sep 2009

Criminal pricing of Merck’s HIV/AIDS drug Isentress challenged by the AIDS Healthcare Foundation

As part of its ongoing campaign to lower drug prices and increase access, AIDS Healthcare Foundation (AHF) today unveiled its latest advocacy campaign challenging Merck and Co. Pharmaceuticals over the steep price of its key HIV/AIDS drug, Isentress (raltegravir). The first phase of the public awareness campaign includes a postcard mailer, scheduled to arrive this week in the mailboxes of residents of Whitehouse Station, New Jersey, where Merck is headquartered.

3 Sep 2009

Update of treatment guidelines for HIV infection recommended by experts

An evaluation of the latest information on the treatment of the adult human immunodeficiency virus (HIV) has led an international panel of experts to update the guidelines and recommendations for antiretroviral treatment of HIV.

3 Aug 2008

Merck announces significant price cuts on two of its AIDS drugs, Stocrin and Isentress

As more than 20,000 people from around the world gather this weekend for the start of the XVII International AIDS Conference in Mexico City, AIDS Healthcare Foundation (AHF) the US-based NGO which provides HIV/AIDS medical care and/or services to more than 79,000 individuals in 20 countries worldwide-including at four free treatment clinics in Mexico-commended Merck & Company (known as Merck, Sharp & Dohme in Mexico) over price cuts on two of its key AIDS drugs in Mexico which were announced yesterday before Sunday's opening of the AIDS conference.

3 Aug 2008

Raltegravir drug combo works against highly resistant strain of HIV

A study involving an international team of scientists has discovered that a new drug when combined with other anti-HIV medications, is particularly effective against a highly resistant strain of the HIV virus.

24 Jul 2008

Gilead initiates phase III trial of Elvitegravir

Gilead Sciences, Inc. has announced that it has begun enrolling patients in a Phase III clinical trial of its investigational antiretroviral agent elvitegravir (GS 9137), a novel oral integrase inhibitor that is being evaluated for the treatment of HIV-1 infection.

22 Jul 2008

Discovery of new drug candidates to combat bird flu

As the specter of a worldwide outbreak of avian or "bird flu" lingers, health officials recognize that new drugs are desperately needed since some strains of the virus already have developed resistance to the current roster of anti-flu remedies.

2 Jul 2008

FDA approves raltegravir new HIV drug

The U.S. Food and Drug Administration (FDA) has approved raltegravir tablets for treatment of Human Immunodeficiency Virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.

17 Oct 2007

AHF challenges Merck over Isentress AIDS drug pricing

AIDS Healthcare Foundation (AHF) has criticized Merck and Co. Pharmaceuticals, for the announced price for its key new HIV/AIDS drug, Isentress (raltegravir), an integrase inhibitor approved by the Food and Drug Administration (FDA) Friday, and priced by the company at nearly $9,900 per patient yearly.

17 Oct 2007